Cargando…

Physiologically based pharmacokinetic modeling of tadalafil to inform pediatric dose selection in children with pulmonary arterial hypertension

Tadalafil, a phosphodiesterase 5 inhibitor, is being investigated as a treatment for pulmonary arterial hypertension (PAH) in children aged 6 months to less than 18 years. Tadalafil pharmacokinetic (PK) data in children less than 2 years old are unavailable, therefore a physiologically based pharmac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rehmel, Jessica, Ferguson‐Sells, Lisa, Morse, Bridget L., Li, Baohui, Dickinson, Gemma L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8846628/ https://www.ncbi.nlm.nih.gov/pubmed/34800000 http://dx.doi.org/10.1002/psp4.12744

Ejemplares similares

Population Pharmacokinetics of Tadalafil in Pediatric Patients with Pulmonary Arterial Hypertension: A Combined Adult/Pediatric Model
por: Ferguson-Sells, Lisa, et al.
Publicado: (2021)

Pharmacokinetics and safety of tadalafil in a paediatric population with pulmonary arterial hypertension: A multiple ascending‐dose study
por: Small, David, et al.
Publicado: (2019)

Physiologically‐Based Pharmacokinetic Modeling of Atorvastatin Incorporating Delayed Gastric Emptying and Acid‐to‐Lactone Conversion
por: Morse, Bridget L., et al.
Publicado: (2019)

The Effect of Grapefruit Juice on the Pharmacokinetics of Tadalafil in Rats
por: Shen, Xiuwei, et al.
Publicado: (2020)

Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling
por: Posada, Maria M., et al.
Publicado: (2020)

Tadalafil Nanoemulsion Mists for Treatment of Pediatric Pulmonary Hypertension via Nebulization
por: Elbardisy, Bassant, et al.
Publicado: (2022)

Efficacy and safety of tadalafil in a pediatric population with pulmonary arterial hypertension: phase 3 randomized, double-blind placebo-controlled study
por: Ivy, Dunbar, et al.
Publicado: (2021)

The role of tadalafil in treated hypertensive patients with erectile dysfunction
por: Grossman, Ehud
Publicado: (2022)

Food Administration and Not Genetic Variants Causes Pharmacokinetic Variability of Tadalafil and Finasteride
por: Villapalos-García, Gonzalo, et al.
Publicado: (2023)

Efficacy of Continuous Dosing of Tadalafil Once Daily vs Tadalafil On Demand in Clinical Subgroups of Men With Erectile Dysfunction: A Descriptive Comparison Using the Integrated Tadalafil Databases
por: Brock, Gerald, et al.
Publicado: (2016)

A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy
por: Washington, Samuel L, et al.
Publicado: (2010)

Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension
por: Sitbon, Olivier, et al.
Publicado: (2020)

Pharmacokinetic Drug Interaction Between Amlodipine and Tadalafil: An Open-Label, Randomized, Multiple-Dose Crossover Study in Healthy Male Volunteers
por: Kim, Hyungsub, et al.
Publicado: (2022)

Population Pharmacokinetics and Pharmacodynamics of the Neutralizing Antibodies Bamlanivimab and Etesevimab in Patients With Mild to Moderate COVID‐19 Infection
por: Chigutsa, Emmanuel, et al.
Publicado: (2021)

Tadalafil: the evidence for its clinical potential in the treatment of pulmonary arterial hypertension
por: Katz, Stuart D.
Publicado: (2007)

Physiologically based pharmacokinetic modeling of daptomycin dose optimization in pediatric patients with renal impairment
por: Ye, Lingling, et al.
Publicado: (2022)

The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension
por: Falk, Jeremy A, et al.
Publicado: (2010)

Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review
por: Henrie, Adam M, et al.
Publicado: (2015)

A Retrospective Evaluation of Allometry, Population Pharmacokinetics, and Physiologically‐Based Pharmacokinetics for Pediatric Dosing Using Clearance as a Surrogate
por: Wu, Qier, et al.
Publicado: (2019)

Physiologically Based Pharmacokinetic (PBPK) Model-Informed Dosing Guidelines for Pediatric Clinical Care: A Pragmatic Approach for a Special Population
por: Freriksen, Jolien J. M., et al.
Publicado: (2022)

Prediction of lisinopril pediatric dose from the reference adult dose by employing a physiologically based pharmacokinetic model
por: Rashid, Memoona, et al.
Publicado: (2020)

Tadalafil in the treatment of erectile dysfunction
por: Coward, Robert M, et al.
Publicado: (2008)

Myopathy with Concurrent Tadalafil and Simvastatin
por: Gargante, Maria Pia, et al.
Publicado: (2009)

The protective effect of single dose tadalafil in contrast-induced nephropathy: An experimental study
por: Özbek, Kerem, et al.
Publicado: (2015)

Treatment Outcomes of Diabetic Patients With Erectile Dysfunction Prescribed High-Dose Tadalafil
por: Condina, Antony, et al.
Publicado: (2023)

Effect of Ticagrelor, a Cytochrome P450 3A4 Inhibitor, on the Pharmacokinetics of Tadalafil in Rats
por: Na, Young-Guk, et al.
Publicado: (2019)

Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug‐Drug Interactions and Pediatric Dose Regimens
por: Cohen‐Rabbie, Sarit, et al.
Publicado: (2021)

Predicting the correct dose in children: Role of computational Pediatric Physiological‐based pharmacokinetics modeling tools
por: Zhou, Xu, et al.
Publicado: (2022)

Use of physiologically‐based pharmacokinetic modeling to inform dosing of the opioid analgesics fentanyl and methadone in children with obesity
por: Gerhart, Jacqueline G., et al.
Publicado: (2022)

Use of Tadalafil for Treating Pulmonary Arterial Hypertension Secondary to Chronic Obstructive Pulmonary Disease
por: Kim, Hyun-Sook, et al.
Publicado: (2007)

Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy
por: Abston, Eric, et al.
Publicado: (2020)

Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe)
por: Hassel, Jessica C., et al.
Publicado: (2017)

Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors
por: Huang, Weize, et al.
Publicado: (2022)

The efficacy of low-dose tadalafil in patients undergoing hemodialysis with end-stage renal disease
por: Bolat, Mustafa Suat, et al.
Publicado: (2017)

Comparison of tadalafil pharmacokinetics after administration of a new orodispersible film versus a film-coated tablet
por: Park, Sang-In, et al.
Publicado: (2018)

Validated UPLC-MS/MS method for the determination of tadalafil in human plasma and its application to a pharmacokinetic study
por: Kim, Kwang-Youl, et al.
Publicado: (2017)

Application of Box-Behnken Design in the Preparation, Optimization, and In-Vivo Pharmacokinetic Evaluation of Oral Tadalafil-Loaded Niosomal Film
por: Abla, Kawthar K., et al.
Publicado: (2023)

Application of Physiologically‐Based and Population Pharmacokinetic Modeling for Dose Finding and Confirmation During the Pediatric Development of Moxifloxacin
por: Willmann, Stefan, et al.
Publicado: (2019)

Physiologically-based pharmacokinetic modeling of nafamostat to support dose selection for treatment of pediatric patients with COVID-19
por: Cho, Yong-Soon, et al.
Publicado: (2022)

Central Serous Chorioretinopathy Associated with Tadalafil
por: Alsarhani, Abdulaziz, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pb9dnip0enqmcpdn0q3daa5j0h